Bellicum to develop PSCA cancer therapies using Agensys technology
14 December 2015 | By Victoria White
Bellicum has been granted rights to develop and commercialise adoptive cell therapies for tumours expressing Prostate Stem Cell Antigen (PSCA) using PCSA technology in-licensed and developed at Agensys...